Communiqués Infant Bacterial Therapeutics AB

Actions

IBT B

SE0008015259

Produits pharmaceutiques

Temps réel estimé Cboe Europe 11:52:05 06/10/2026			Varia. 5j.	Varia. 1 janv.
70,60 ^SEK	+2,32%		+2,47%	+39,60%

21/09	Neuf actions ont atteint un nouveau plus haut sur 52 semaines aujourd'hui à la Bourse de Stockholm	FW
21/09	IBT obtient une réunion avec la FDA concernant l'IBP-9414	FW

Communiqués

21/09	Infant Bacterial Therapeutics : FDA Grants Infant Bacterial Therapeutics AB's Request for a Type B Pre-BLA Meeting	PU
21/09	FDA Grants Infant Bacterial Therapeutics AB’s Request for a Type B Pre-BLA Meeting	AQ
18/09	NOMINATION COMMITTEE FOR INFANT BACTERIAL THERAPEUTICS AB (PUBL) FOR THE ANNUAL GENERAL MEETING 2027	AQ
26/08	Infant Bacterial Therapeutics () : Interim report January 1 - June 30, 2026	PU
07/07	Infant Bacterial Therapeutics : CFO Leaves the Company	PU
07/05	Annual General Meeting of Infant Bacterial Therapeutics	AQ
02/04	Notice of Annual General Meeting of Infant Bacterial Therapeutics	AQ
30/03	Notice of Annual General Meeting of Infant Bacterial Therapeutics	AQ
27/03	Infant Bacterial Therapeutics AB publishes the Annual Report for 2025	AQ
03/03	Infant Bacterial Therapeutics (IBT) publishes results from ”The Connection Study” in Pediatric Research	AQ
11/12	Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product	AQ
25/11	IBT changes the IBP-9414 pathway for approval following discussions with the FDA	AQ
20/11	Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for production of drug substance	AQ
13/11	Infant Bacterial Therapeutics () : Interim report January 1 - September 30, 2025	PU
13/11	Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2025	AQ
20/10/25	Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2026	AQ
13/10/25	Registration work for IBT's drug candidate IBP-9414 continues in the US and Europe	AQ
10/09/25	Infant Bacterial Therapeutics : IBT presented “Avoiding the severe consequences of NEC” at the NEC Society Symposium in Chicago	PU
20/08/25	Infant Bacterial Therapeutics () : Interim report January 1 - June 30, 2025	PU
20/08/25	Infant Bacterial Therapeutics AB (publ) Interim report January 1 – June 30, 2025	AQ
14/05/25	Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki	AQ
08/05/25	Annual General Meeting of Infant Bacterial Therapeutics	AQ
08/05/25	Infant Bacterial Therapeutics : IBT Submits Clinical Study Report for ‘The Connection Study' to the FDA	PU
07/05/25	Infant Bacterial Therapeutics () : Interim report January 1 - March 31, 2025	PU
07/05/25	Infant Bacterial Therapeutics AB (publ) Interim report January 1 – March 31, 2025	AQ